Chronic Urticaria – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of chronic urticaria (CU) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of CU for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature pharmaceutical markets of the United States, Europe, and Japan.

Clarivate Epidemiology’s CU forecast will answer the following questions:

• Of all people with CU, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
• Of all people diagnosed with CU, how many in each developed country are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CU over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts the following CU patient populations:

• Diagnosed 12-month prevalent cases of CU.
• Total 12-month prevalent cases of spontaneous CU.
• Total 12-month prevalent cases of inducible CU.
• Total 12-month prevalent cases of spontaneous and inducible (overlap) CU.
• Diagnosed 12-month prevalent cases of spontaneous CU.
• Undiagnosed 12-month prevalent cases of spontaneous CU.
• Diagnosed 12-month prevalent cases of inducible CU.
• Undiagnosed 12-month prevalent cases of inducible CU.
• Diagnosed 12-month prevalent cases of spontaneous and inducible (overlap) CU.
• Undiagnosed 12-month prevalent cases of spontaneous and inducible (overlap) CU.
• Diagnosed drug-treated prevalent cases of spontaneous CU.
• Diagnosed non-drug-treated prevalent cases of spontaneous CU.
• Diagnosed drug-treated prevalent cases of inducible CU.
• Diagnosed non-drug-treated prevalent cases of inducible CU.

Note: Coverage may vary by country.